BiVictriX Therapeutics plc Shares Now Trading on JP Jenkins

BiVictriX Therapeutics plc, a UK-based drug discovery company, has announced that its shares are now trading on the JP Jenkins platform. The company is developing highly selective cancer therapeutics with reduced treatment-related toxicities.

BiVictriX utilizes an innovative approach to create bispecific antibody drug conjugates (Bi-Cygni® ADCs). These therapeutics target cancer-specific antigen pairs while minimizing effects on healthy cells. The company is headquartered in Alderley Park, Manchester.

JP Jenkins offers a share trading venue for unlisted assets, facilitating trades through stockbrokers. Shareholders and investors can execute trades during normal business hours. Indicative pricing and transaction history are available on the JP Jenkins website.

CEO Tiffany Thorn expressed enthusiasm about the move to JP Jenkins, emphasizing the platform's potential for growth and development. Veronika Oswald, Commercial Director of JP Jenkins, welcomed BiVictriX, highlighting the company's groundbreaking work in the biotech sector.